tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2019-97-4-56-62tiblj-1264Research ArticleОБЗОРREVIEWКардиотоксические свойства фторхинолонов и бедаквилинаCardiac toxicity of fluoroquinolones and bedaquilineМожокинаГ. Н.MozhokinаG. N.

Можокина Галина Николаевна - доктор медицинских наук, ведущий научный сотрудник лаборатории инфекционной иммунологии, патологии и биотехнологии.

Galina N. Mozhokina - Doctor of Medical Sciences, Leading Researcher of Laboratory for Infectious Immunology, Pathology and Biotechnology.

mojokina@mail.ruСамойловаА. Г.SаmoylovаA. G.

Самойлова Анастасия Геннадьевна - доктор медицинских наук, заместитель директора по науке.

127473, Москва, ул. Достоевского, д. 4, тел.: 8 (495) 681-07-46

Anastasiya G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research.

a.samoilova.nmrc@mail.ruФГБУ Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеванийРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, RussiaRussian Federation2019070520199745662Copyright © Можокина Г.Н., Самойлова А.Г., 20192019Можокина Г.Н., Самойлова А.Г.Mozhokinа G.N., Sаmoylovа A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1264

В обзоре проанализированы данные литературы о влиянии фторхинолонов и бедаквилина на проводящую систему сердца. Представлена зависимость кардиотоксического действия фторхинолонов от их влияния на калиевые каналы кардиомиоцитов. Показана значимость сопутствующих факторов (уровня калия в крови, наличия заболевания сердца, генетически детерминированного количества HERG-рецепторов в миокарде, сопутствующей медикаментозной терапии) в развитии кардиотоксического действия фторхинолонов и бедаквилина. 

The review analyzes data on the impact of fluoroquinolones and bedaquiline on the cardiac conduction system. The dependence of the cardiotoxic effect of fluoroquinolones on their influence on the potassium channels of cardiomyocytes is presented. The article demonstrates the importance of concomitant factors (potassium level in the blood, concurrent heart disorders, a genetically determined amount of HERG receptors in the myocardium, concomitant drug therapy) in the development of the cardiac toxicity caused by fluoroquinolones and bedaquiline. 

кардиотоксичностьинтервал QTфторхинолоныбедаквилинcardiac toxicityQT intervalfluoroquinolonesbedaquilineReferencesАбулкасимов С. П., Пулатов Ж. А., Мухамедов Х. Х., Саидорипов К. А. Результаты применения бедаквилина в комплексном лечении больных туберкулезом легких с широкой лекарственной устойчивостью // Молодой ученый. ‒ 2017. ‒ № 5 (2). ‒ С. 4-5. ‒ URL https://moluch.ru/archive/139/39857/Аbulkasimov S.P., Pulatov Zh.А., Mukhamedov Kh. Kh., Saidoripov K.А. Outcomes of treatment with bedaquiline within comprehensive treatment of pulmonary tuberculosis patients with extensive drug resistance. Molodoy Ucheny, 2017, no. 5 (2), pp. 4-5. (In Russ.) Available: https://moluch.ru/archive/139/39857/Буданов С. В. Нежелательные эффекты фторхинолонов в клинической практике (результаты мониторинга нежелательных побочных эффектов) // Московский хирургический журнал. ‒ 2010. ‒ № 3. ‒ С. 17-19.Budanov S.V. Adverse effects caused by fluoroquinolones in the clinical practice (results of adverse effects monitoring). Moskovskiy Khirurgicheskiy Journal, 2010, no. 3, pp. 17-19. (In Russ.)Галеева Ж. А., Зырянов С. К. Кардиотоксичность макролидных антибиотиков // Клин. микробиол. антимикроб. химиотер. ‒ 2015. ‒ Т. 17, № 4. ‒ С. 262-266.Galeeva Zh.А., Zyryanov S.K. Cardiac toxicity of macrolide antibiotics. Klin. Microbiol. Antimicrob. Khimioter., 2015, vol. 17, no. 4, pp. 262-266. (In Russ.)Жукова Е. М., Колпакова Т. А., Мышкова Е. П., Рейхруд Т. А. Опыт применения бедаквилина и линезолида в комплексном лечении больного туберкулезом легких с широкой лекарственной устойчивостью M. tuberculosis // Туб. и болезни легких. ‒ 2016. ‒ Т. 94, № 10. ‒ С. 62-66.Zhukova E.M., Kolpakova T.А., Myshkova E.P., Reykhrud T.А. Experience of using bedaquiline and linezolid within comprehensive treatment of the pulmonary tuberculosis patient with extensive drug resistance of M. tuberculosis. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 10, pp. 62-66. (In Russ.)Модел С. В., Кузьмина А. В., Галстян Г. М., Соколов А. Н., Троицкая В. В. Лечение пароксизмов желудочковой тахикардии “torsades-de-pointes” у больной с синдромом удлиненной электрической систолы, развившимся в результате антибактериальной терапии // Гематология и трансфузиология. ‒ 2015. ‒ Т. 60, № 2. ‒ С. 44-51.Model S.V., Kuzmina А.V., Galstyan G.M., Sokolov А.N., Troitskaya V.V. Management of ventricular tachycardia paroxysms of torsades-de-pointes in the female patient with the syndrome of extended electrical systole developed due to anti-bacterial therapy. Gematologiya i Transfuziologiya, 2015, vol. 60, no. 2, pp. 44-51. (In Russ.)Парпиева Н. Н., Абулкасимов С. П., Пулатов Ж. А., Мухторов Ш. Н., Айтжанова А. У. Побочные нежелательные явления при применении бедаквилина в режиме лечения больных с ШЛУ ТБ // Молодой ученый. ‒ 2018. ‒ № 10 (1). ‒ С. 31-33. ‒ URL https://moluch.ru/archive/196/49419/ (дата обращения: 02.10.2018).Parpieva N.N., Аbulkasimov S.P., Pulatov Zh.А., Mukhtorov Sh.N., Аytzhanova А.U. Adverse events caused by bedaquiline in the treatment of XDR TB patients. Molodoy Ucheny, 2018, no. 10 (1), pp. 31-33. (In Russ.) Available: https://moluch.ru/archive/196/49419/ (Accessed as of 02.10.2018).Скрягина Е. М., Гуревич Г. Л., Солодовникова В. В., Дюсьмикеева М. И. и др. Опыт применения новых режимов лечения туберкулеза с множественной и широкой лекарственной устойчивостью возбудителя в Республике Беларусь // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 8. ‒ С. 5-15.Skryagina E.M., Gurevich G.L., Solodovnikova V.V., Dyusmikeeva M.I. et al. Experience of treating multiple/extensive drug resistant tuberculosis with new regimens in Belarus Republic. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 5-15. (In Russ.)Тихонова Л. Ю., Соколова В. В., Тарасюк И. А., Екименко А. М. и др. Опыт применения препарата бедаквилин у больных туберкулезом с множественной лекарственной устойчивостью возбудителя в Амурской области // Туб. и болезни легких. – 2018. – Т. 96, № 6. – С. 45-50.Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M. et al. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя. – М., 2015. ‒ С. 14-28.Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. Moscow, 2015, pp. 14-28.Фурман Н. В., Шматова С. С. Клиническое значение удлинения интервалов QT и QTC на фоне приема лекарственных препаратов // Рациональная фармакотерапия в кардиологии. ‒ 2013. ‒ Т. 9, № 3. ‒ С. 311-315.Furman N.V., Shmatova S.S. Clinical value of QT and QTc intervals prolongation due to in-take drugs. Ratsionalnaya Farmakoterapiya v Kardiologii, 2013, vol. 9, no. 3, pp. 311-315. (In Russ.)Шилов А. М., Мельник М. В., Санодзе И. Д. Диагностика, профилактика и лечение синдрома удлинения QT интервала. Методические рекомендации. ‒ М., 2001.Shilov А.M., Melnik M.V., Sanodze I.D. Diagnostika, profilaktika i lechenie sindroma udlineniya QT intervala. Metodicheskie rekomendatsii. [Diagnostics, prevention and management of QT interval prolongation. Guidelines]. Moscow, 2001.Algra A., Tijssen J. G., Roelandt J. R. et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest // Circulation. ‒ 1991. ‒ Vol. 83. ‒ Р. 1888-1894.Algra A., Tijssen J.G., Roelandt J.R. et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation, 1991, 83, pp. 1888-1894.Al-Khatib S. M., LaPointe N. M., Kramer J. M., Califf R. M. What clinicians should know about the QT interval // J. Am. Med. Assoc. 2003. ‒ Vol. 289 (16). ‒ Р. 2120-2127.Al-Khatib S.M., LaPointe N.M., Kramer J.M., Califf R.M. What clinicians should know about the QT interval. J. Am. Med. Assoc., 2003, vol. 289 (16), pp. 2120-2127.Anzueto A., Niederman M. S., Pearle J. et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy // Clin. Infect. Dis. ‒ 2006. ‒ Vol. 1. ‒ Р. 73-81.Anzueto A., Niederman M.S., Pearle J. et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis., 2006, vol. 1, pp. 73-81.Ball P., Mandell L., Niki Y., Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials // Drug Saf. ‒1999. ‒ Vol. 21. ‒ Р. 407-421.Ball P., Mandell L., Niki Y., Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf., 1999, vol. 21, pp. 407-421.Ball P. Quinolone induced QT interval prolongation: a not unexpected class effect // J. Antimicrob. Chemother. ‒ 2000. ‒ Vol. 45. ‒ Р. 557-559.Ball P. Quinolone induced QT interval prolongation: a not unexpected class effect. J. Antimicrob. Chemother., 2000, vol. 45, pp. 557-559.Conder M. L., Lawrence J. H., Levesque P. C., Blanar M. A. Inhibition of the HERG potassium ion channel by fluoroquinolone antibiotics: correlation with the risk for clinically significant QT interval prolongation (abstr.). Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Washington, DC: American Society for Microbiology, 2000: 474.Conder M.L., Lawrence J.H., Levesque P.C., Blanar M.A. Inhibition of the HERG potassium ion channel by fluoroquinolone antibiotics: correlation with the risk for clinically significant QT interval prolongation (abstr.). Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17-20, 2000. Washington DC, American Society for Microbiology, 2000, 474.Dale K. M., Lertsburapa K., Kluger J et al. Moxifloxacin and torsade de pointes // Ann. Pharmacother. ‒ 2007. ‒ Vol. 41, № 2. ‒ Р. 336-340.Dale K.M., Lertsburapa K., Kluger J et al. Moxifloxacin and torsade de pointes. Ann. Pharmacother., 2007, vol. 41, no. 2, pp. 336-340.Demolis J. L., Kubitza D., Tenneze L., Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects // Clin. Pharmacol. Ther. ‒ 2000. ‒ Vol. 68, № 6. ‒ Р. 658-666.Demolis J.L., Kubitza D., Tenneze L., Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther., 2000, vol. 68, no. 6, pp. 658-666.Fenichel R., Malik M., Antzelevitch C. et al. Drug-induced torsades de pointes and implications for drug development // J. Cardiovasc. Electrophysiol. ‒ 2004. ‒ Vol. 15. ‒ Р. 475-495.Fenichel R., Malik M., Antzelevitch C. et al. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol., 2004, vol. 15, pp. 475-495.Ferguson J. Fluoroquinolone phototoxicity – moxifloxacin in context.// 1st Intern. Moxifloxacin Symp., Berlin, 1999 / Ed. Mandell L.Springer-Verlag. ‒ 2000. ‒ P. 134-137.Ferguson J. Fluoroquinolone phototoxicity - moxifloxacin in context. 1st Intern. Moxifloxacin Symp., Berlin, 1999, Ed. Mandell L.Springer-Verlag. 2000, pp. 134-137.Food and Drug Administration. Drug development and drug interactions: Table of substrates, inhibitors and inducers. 2011 //www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#classInhibit.Food and Drug Administration. Drug development and drug interactions: Table of substrates, inhibitors and inducers. 2011. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#classInhibit.Fox G. J., Menzies D. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis // Infect. Dis. Ther. ‒ 2013. ‒ Vol. 2. ‒ Р. 123-144.Fox G.J., Menzies D. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infect. Dis. Ther., 2013, vol. 2, pp. 123-144.Hannibal G. B., Hasanien A. A., Pickham D. ECG Challenges: Measurement and Rate Correction of the QT Interval // AACN Advanced Crit. Care. ‒ 2013. ‒ Vol. 24, № 1. ‒ Р. 90-96.Hannibal G.B., Hasanien A.A., Pickham D. ECG Challenges: Measurement and Rate Correction of the QT Interval. AACN Advanced Crit. Care, 2013, vol. 24, no. 1, pp. 90-96.Hondeghem L. M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic // Circulation. ‒ 2001. ‒ Vol. 103. ‒ Р. 2004-2013.Hondeghem L.M., Carlsson L., Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation, 2001, vol. 103, pp. 2004-2013.Hondeghem L. M. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability) // Novartis Found Symp. ‒ 2005. ‒ Vol. 266. ‒ Р. 235-244.Hondeghem L.M. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). Novartis Found Symp., 2005, vol. 266, pp. 235-244.Hondeghem L. M. Use and abuse of QTand TRIaD in cardiac safety research: importance of study design and conduct // Eur. J. Pharmacol. ‒ 2008. ‒ Vol. 584. ‒ Р. 1-9.Hondeghem L.M. Use and abuse of QTand TRIaD in cardiac safety research: importance of study design and conduct. Eur. J. Pharmacol., 2008, vol. 584, pp. 1-9.Iannini P. Prolongation of QT interval is probably a class effect of fluoroquinolones // BMJ. ‒ 2001. ‒ Vol. 322. ‒ Р. 46.Iannini P. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ, 2001, vol. 322, pp. 46.International Conference on Harmonization. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs // www.fda.dov/RegylatoryInformation/Guidances/ucm129335.htm.International Conference on Harmonization. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. www.fda.dov/RegylatoryInformation/Guidances/ucm129335.htm.Kang J., Wang L., Chen X.-L. et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG // Mol. Pharmacol. ‒ 2001. ‒ Vol. 59. ‒ Р. 122-126.Kang J., Wang L., Chen X.-L. et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol., 2001, vol. 59, pp. 122-126.Lipsky B. A., Baker C. A. Fluoroquinolone toxicity profiles: a review focusing on newer agents // Clin. Infect. Dis. ‒ 1999. ‒ Vol. 28, № 2. ‒ Р. 352-364.Lipsky B.A., Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis., 1999, vol. 28, no. 2, pp. 352-364.Mandell L. A., Ball P., Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas // Clin. Infect. Dis. ‒ 2001. ‒ Vol. 32, № 1. ‒ Р. 72-79.Mandell L.A., Ball P., Tillotson G. Antimicrobial safety and tolerability: differences and dilemmas. Clin. Infect. Dis., 2001, vol. 32, no. 1, pp. 72-79.Morganroth J., Dimar J. P., Anzueto A. et al., A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia // Chest. ‒ 2005. ‒ Vol. 128, № 5. ‒ Р. 3398-3406.Morganroth J., Dimar J.P., Anzueto A. et al., A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest, 2005, vol. 128, no. 5, pp. 3398-3406.Noel G. J., Natarajan J., Chien S. et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses // Clin. Pharmacol. Ther. ‒ 2003. ‒ Vol. 73. ‒ P. 292-303.Noel G.J., Natarajan J., Chien S. et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin. Pharmacol. Ther., 2003, vol. 73, pp. 292-303.Nykamp D. L., Blackmon C. L., Schmidt P. E., Roberson A. G. QTc prolongation associated with combination therapy of levofloxacin, imipramine and fluoxetine // Ann. Pharmacother. ‒ 2005. ‒ Vol. 39, № 3. ‒ Р. 543-546.Nykamp D.L., Blackmon C.L., Schmidt P.E., Roberson A.G. QTc prolongation associated with combination therapy of levofloxacin, imipramine and fluoxetine. Ann. Pharmacother., 2005, vol. 39, no. 3, pp. 543-546.Owens R. C. QT prolongation with antimicrobial agents: under-standing the significance // Drugs. ‒ 2004. ‒ Vol. 64, № 10. ‒ P. 1091-1124.Owens R.C. QT prolongation with antimicrobial agents: under-standing the significance. Drugs, 2004, vol. 64, no. 10, pp. 1091-1124.Owens R. C. Jr., Ambrose P. G. Antimicrobial safety: focus on fluoroquinolones // Clin. Infect. Dis. ‒ 2005. ‒ Vol. 41, № 2. ‒ Р. 144-157.Owens R.C.Jr., Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis., 2005, vol. 41, no. 2, pp. 144-157.Poluzzi E., Raschi E., Motola D., Moretti U., de Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System // Drug. Saf. ‒ 2010. ‒ Vol. 33, № 4. ‒ Р. 303-314.Poluzzi E., Raschi E., Motola D., Moretti U., de Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug. Saf., 2010, vol. 33, no. 4, pp. 303-314.Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB), 2018, WHO // http://roftb.ru/netcat_files/doks2018/2018-08-28-WHO_MDRTB_en.pdf.Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB), 2018, WHO. http://roftb.ru/netcat_files/doks2018/2018-08-28-WHO_MDRTB_en.pdf.Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: Data analysis report Prepared for: The World Health Organization MARCH 8, 2017.Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: Data analysis report Prepared for: The World Health Organization MARCH 8, 2017.Roden D. M. Acquired long QT syndromes and the risk of proarrhythmia // J. Cardiovasc. Electrophysiol. ‒ 2000. ‒ Vol. 11, № 8. ‒ Р. 938-940.Roden D.M. Acquired long QT syndromes and the risk of proarrhythmia. J. Cardiovasc. Electrophysiol., 2000, vol. 11, no. 8, pp. 938-940.Sanguinetti M. C., Jiang C., Curran M. E., Keating M. T. A mechanisticlink between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel // Cell. ‒ 1995. ‒ Vol. 81. ‒ P. 299-307.Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanisticlink between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell, 1995, vol. 81, pp. 299-307.Satoh Y., Sugiyama A., Chiba K. et al. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring // J. Cardiovasc. Pharmacol. ‒ 2000. ‒ Vol. 36, № 4. ‒ Р. 510-515.Satoh Y., Sugiyama A., Chiba K. et al. QT-prolonging effects of sparfloxacin, a fluoroquinolone antibiotic, assessed in the in vivo canine model with monophasic action potential monitoring. J. Cardiovasc. Pharmacol., 2000, vol. 36, no. 4, pp. 510-515.Sauer A. J., Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk // Circulation. ‒ 2012. ‒ Vol. 125. ‒ Р. 1684-1694.Sauer A.J., Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation, 2012, vol. 125, pp. 1684-1694.Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents // Expert. Opin. Pharmacother. ‒ 2006. ‒ Vol. 7, № 6. ‒ Р. 639-651.Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert. Opin. Pharmacother., 2006, vol. 7, no. 6, pp. 639-651.Simkó J., Csilek A., Karászi J., Lorincz I. Proarrhythmic potential of antimicrobial agents // Infection. ‒ 2008. ‒ Vol. 36, № 3. ‒ Р. 194-206.Simkó J., Csilek A., Karászi J., Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection, 2008, vol. 36, no. 3, pp. 194-206.Stahlmann R., Lode H. Fluoroquinolones in the elderly: safety considerations // Drugs. Aging. ‒ 2003. ‒ Vol. 20, № 4. ‒ Р. 289-302.Stahlmann R., Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging, 2003, vol. 20, no. 4, pp. 289-302.Straus M., Sturkenboom M. C., Bleumink G. S. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death // Eur. Heart. J. ‒ 2005. ‒ Vol. 26. ‒ Р. 2007-2012.Straus M., Sturkenboom M.C., Bleumink G.S. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J., 2005, vol. 26, pp. 2007-2012.Tristani-Firouzi M., Chen J., Mitcheson J. S., Sanguinetti M. C. Molecular biology of K(+) channels and their role in cardiac arrhythmias // Am. J. Med. ‒ 2001. ‒ Vol. 110, № 1. ‒ Р. 50-59.Tristani-Firouzi M., Chen J., Mitcheson J.S., Sanguinetti M.C. Molecular biology of K(+) channels and their role in cardiac arrhythmias. Am. J. Med., 2001, vol. 110, no. 1, pp. 50-59.Veyssier P., Voirot P., Begaud B. et al. Cardiac tolerance of moxifloxacin: Clinical experience from a large observational French study in usual medical practice (IMMEDIAT study) // Med. Mal. Infect. ‒ 2006. ‒ Vol. 36, № 10. ‒ Р. 505-512.Veyssier P., Voirot P., Begaud B. et al. Cardiac tolerance of moxifloxacin: Clinical experience from a large observational French study in usual medical practice (IMMEDIAT study). Med. Mal. Infect., 2006, vol. 36, no. 10, pp. 505-512.Waldo A. L., Camm A. J., deRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol // Lancet. ‒ 1996. ‒ Vol. 348. ‒ Р. 7-12.Waldo A.L., Camm A.J., deRuyter H. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol. Lancet, 1996, vol. 348, pp. 7-12.Zareba W. Drug induced QT prolongation // Cardiol. J. ‒ 2007. ‒ Vol. 14, № 6. ‒ Р. 523-533.Zareba W. Drug induced QT prolongation. Cardiol. J., 2007, vol. 14, no. 6, pp. 523-533.

The authors declare that there are no conflicts of interest present.